T-705 (Favipiravir)

Catalog No. A11590

T-705 (Favipiravir)是一种有效的选择性RNA-dependent RNA polymerase抑制剂，在体外和体内均表现出有效的抗流感病毒活性。

Product Citations

Satoko Yamaoka, .et al. Development of accelerated high-throughput antiviral screening systems for emerging orthomyxoviruses, Antiviral Res, 2022, Apr;200:105291 PMID: 35296419
Crystal A Mendoza, .et al. The NF- κB inhibitor, SC75741, is a novel antiviral against emerging tick-borne bandaviruses, Antiviral Res, 2021, Jan;185:104993 PMID: 33296695
Liva Checkmahomed, .et al. In Vitro Combinations of Baloxavir Acid and Other Inhibitors against Seasonal Influenza A Viruses, Viruses, 2020, Oct; 12(10): 1139 PMID: 33049959
JE Comer, .et al. Filovirus Virulence in Interferon α,β and γ Double Knockout Mice, and Treatment with Favipiravir, Viruses, 2019, Feb 3;11(2). pii: E137 PMID: 30717492
Ma J, .et al. Enhancing the antiviral potency of ER α-glucosidase inhibitor IHVR-19029 against hemorrhagic fever viruses in vitro and in vivo, Antiviral Res, 2018, Feb;150:112-122 PMID: 29253498
Ji-Ae Kim, .et al. Favipiravir and Ribavirin Inhibit Replication of Asian and African Strains of Zika Virus in Different Cell Models, Viruses, 2018, Feb; 10(2): 72 PMID: 29425176
Haejin Chun, .et al. Efficient antiviral co-delivery using polymersomes by controlling the surface density of cell-targeting groups for influenza A virus treatment, Polym Chem, 2018, 9: 2116-2123
Baz M, .et al. Combination Therapy with Oseltamivir and Favipiravir Delays Mortality but Does Not Prevent Oseltamivir Resistance in Immunodeficient Mice Infected with Pandemic A(H1N1) Influenza Virus, Viruses, 2018, Nov 3;10(11) PMID: 30400276
Sehee Park, .et al. Combination Effects of Peramivir and Favipiravir against Oseltamivir-Resistant 2009 Pandemic Influenza A(H1N1) Infection in Mice, PLoS One., 2014, 9(7): e101325 PMID: 24992479

Technical details

Catalog Num	A11590
M. Wt	157.1
Formula	C5H4FN3O2
Purity	>98%
Storage	at -20°C 3 years Powder
CAS No.	259793-96-9
Synonyms	T705, T 705
SMILES	C1=C(N=C(C(=O)N1)C(=O)N)F

Biological Activity

T-705 (Favipiravir)是一种有效的选择性RNA-dependent RNA polymerase抑制剂，在体外和体内均表现出有效的抗流感病毒活性。

Targets

RNA-dependent RNA polymerase

Solubility *

In vitro	DMSO	29 mg/mL (184.59 mM)
	Water	Warmed: 5 mg/mL (31.82 mM)
	Ethanol	Warmed: 21 mg/mL (133.67 mM)
* <1 mg/ml means slightly soluble or insoluble. * Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Preparing Stock Solutions

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
0.1 mM	63.65 mL	318.27 mL	636.54 mL
0.5 mM	12.73 mL	63.65 mL	127.31 mL
1 mM	6.37 mL	31.83 mL	63.65 mL
5 mM	1.27 mL	6.37 mL	12.73 mL

*The above data is based on the productmolecular weight 157.1. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.